<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803309</url>
  </required_header>
  <id_info>
    <org_study_id>P05498</org_study_id>
    <nct_id>NCT00803309</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients</brief_title>
  <acronym>OPTEX2/3</acronym>
  <official_title>Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HepNet Study House, German Liverfoundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Clinical Trial Center GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HepNet Study House, German Liverfoundation</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we intend to treat patients with chronic hepatitis C of genotype 2 or 3 having
      characteristics associated with poor treatment response for additional 12 or 24 weeks beyond
      the standard treatment of PEG-IFN alpha-2b plus ribavirin.

      The objective of this study is to compare the efficacy of a treatment extension of 12 versus
      24 weeks in patients with HCV-genotypes 2 and 3 who are treated with 1.5 µg/kg PEG-IFN
      alpha-2b and 800-1400 mg ribavirin (standard dose) for 24 weeks (standard duration) and who
      are not HCV-RNA negative (&lt; 15 IU/ml) after 4 weeks of standard treatment but HCV-RNA
      negative after 16-24 weeks of standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    At the end of the planned recruitment period the expected number of subjects could not be
    included in the trial.
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)</measure>
    <time_frame>48 weeks (arm A) or 36 weeks (arm B)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response rates (HCV-RNA negative in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) at the end of therapy</measure>
    <time_frame>24 weeks (arm A) or 12 weeks (arm B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical responses as determined by ALT and AST levels at the end of treatment and at the end of follow up.</measure>
    <time_frame>Arm A: 24 and 24 weeks, arm B: 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and frequency of adverse event</measure>
    <time_frame>48 weeks (arm A) or 36 weeks (arm B)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of quality of life</measure>
    <time_frame>48 weeks (arm A) or 36 weeks (arm B)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon alpha-2b</intervention_name>
    <description>1.5 µg/kg once weekly, syringe, 24 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>800-1400 mg per os, daily, tablets, 24 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated Interferon alpha-2b</intervention_name>
    <description>1.5 µg/kg once weekly, syringe, 12 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>800-1400 mg per os, daily, tablets, 12 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with HCV-genotype 2/3 chronic hepatitis C documented by
             detectable plasma HCV RNA (&gt; 15 IU/mL) and positivity of anti-HCV antibodies

          -  Age ≥ 18 years

          -  Compensated liver disease (Child-Pugh Grade A clinical classification)

          -  Negative urine or blood pregnancy test (one of the both; for women of childbearing
             potential) documented within the 24-hour period prior to the first dose of study
             drug. Additionally, all fertile males and females must be using two forms of
             effective contraception during treatment and during the 7 months after treatment end.
             This includes using birth control pills (no interaction with investigational drugs),
             IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a
             post-menopausal state. At least one contraception method must be of barrier method

          -  Ongoing treatment with 1.5 µg/kg Peg-Interferon alpha-2b (PegIntron®) and &gt; 10.6
             mg/kg ribavirin (Rebetol®)

          -  No rapid virological response (HCV-RNA positive after week 4 of the ongoing therapy)

          -  Willingness to give written informed consent and willingness to participate to and to
             comply with the study protocol

        Exclusion Criteria:

          -  Women with ongoing pregnancy or breast feeding

          -  Male partners of women who are pregnant

          -  Positive tests at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBeAg,
             anti-HIV, HIV-RNA

          -  History or other evidence of a medical condition associated with chronic liver
             disease other than HCV associated (e.g., hemochromatosis, autoimmune hepatitis,
             alcoholic liver disease, toxin exposures)

          -  History or other evidence of bleeding from esophageal varices or other conditions
             consistent with decompensated liver disease

          -  Patients with liver cirrhosis with a lesion suspicious for hepatic malignancy on the
             screening

          -  Absolute neutrophil count (ANC) &lt;750 cells/mm3 at screening

          -  Platelet count &lt;50,000 cells/mm3 at screening

          -  Hb &lt;10 g/dl at screening

          -  Dose modification of Peg-Interferon alpha-2b (PegIntron®) or ribavirin (Rebetol®)
             during the first 4 weeks of the ongoing therapy

          -  Interferon alpha or ribavirin therapy at any time point before the actual ongoing
             treatment

          -  Less than 80% adherence to treatment of the ongoing treatment until randomization
             (week 20-22 of ongoing treatment)

          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening

          -  History of severe psychiatric disease, especially depression (ICD 10 codes F30-F33).
             Severe psychiatric disease is defined as treatment with an antidepressant medication
             or a major tranquilizer at therapeutic doses for major depression or psychosis,
             respectively, for at least 3 months at any previous time. Patients are excluded if
             any history of suicidal attempts is evident. If hospitalization for psychiatric
             disease, or a period of disability due to a psychiatric disease are documented,
             psychiatric consultation is mandatory. Patients with a mild or moderate psychiatric
             disease (ICD 10 codes F32.0, F32.1, F33.0, F33.1) are only allowed to be included
             into the trial if a regular monitoring by a psychiatrist is performed during the
             trial

          -  History of a severe seizure disorder or current anticonvulsant use

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic
             anemia, scleroderma, severe psoriasis, rheumatoid arthritis)

          -  History or any other evidence of autoimmune diseases

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation

          -  History of significant cardiac disease that could be worsened by acute anemia (e.g.
             NYHA Functional Class III or IV, myocardial infarction within 6 months prior to
             treatment with Peg-Interferon/ribavirin therapy, ventricular tachyarrhythmias
             requiring ongoing treatment, unstable angina)

          -  Evidence of thyroid disease that is poorly controlled on prescribed medications

          -  Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration)

          -  History of major organ transplantation with an existing functional graft

          -  History or other evidence of severe illness, malignancy or any other conditions which
             would make the patient, in the opinion of the investigator, unsuitable for the study

          -  History of any systemic anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of
             study drug or the expectation that such treatment will be needed at any time during
             the study

          -  Patients with evidence for tuberculosis

          -  Drug abuse within 6 months prior to the first dose of study drug and excessive
             alcohol consumption. Patients on methadone/polamidone/buprenorphine programs are not
             excluded

          -  Any investigational drug and/or participation in another clinical study prior 6
             months to the actual ongoing antiviral treatment

          -  Limited contractual capability
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P. Manns, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum, Med. Klinik für Gastroenterologie und Hepatologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatologische Schwerpunktpraxis im bng</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Infektiologiezentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. J. Gölz</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Naumann</name>
      <address>
        <city>Berlin</city>
        <zip>10627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Meyer</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ärztehaus Leipziger Straße</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Wilhelms-Universität, Med. Klinik und Poliklinik I</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Burghausen/Altötting, Med. Klinik II</name>
      <address>
        <city>Burghausen/Altötting</city>
        <zip>84489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatologische Schwerpunktpraxis im bng</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärztliche Gemeinschaftspraxis</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitanus GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Zentrum Gastroenterologie und Endokrinologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Institut für interdiziplinäre Infektiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPM-Studycenter GmbH &amp; Co. KG</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Klinik für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtätsklinikum Hamburg-Eppendorf;Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leberpraxis Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum Innere Medizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. S. Holm</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät der Universität Heidelberg, Innere Medizin IV</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatologische Schwerpunktpraxis im bng</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken des Saarlandes, Innere Medizin II, Gastroenterologie</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin der FSU</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis</name>
      <address>
        <city>Kiel</city>
        <zip>24146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Allgemeine Innere Medizin</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr.Simon</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Schleswig-Holstein, Campus Lübeck, Med. Klinik I</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg Universität Med. Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Klinikum Mannheim, Med. Klinik II</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatologische Schwerpunktpraxis im bng</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern, Med. Klinik 2</name>
      <address>
        <city>München</city>
        <zip>81366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Med. Klinik und Poliklinik B</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Theresien-Krankenhaus</name>
      <address>
        <city>Nürnberg</city>
        <zip>90491</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef Hospital</name>
      <address>
        <city>Oberhausen</city>
        <zip>46045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatologische Schwerpunktpraxis im bng</name>
      <address>
        <city>Offenbach</city>
        <zip>63065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Josefs-Klinik, Med. Klinik</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus, Med. Klinik II</name>
      <address>
        <city>Rotenburg (Wuemme)</city>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. A. Trein</name>
      <address>
        <city>Stuttgart</city>
        <zip>70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen Medizinische Klinik I</name>
      <address>
        <city>Tübingen</city>
        <zip>70206</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Abteilung für Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Poliklinik der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-hepatitis.de</url>
    <description>The network of competence for hepatitis (Hep-Net) will support the nation-wide research of viral hepatitis and will develop uniform diagnostic and therapeutic standards for five years.</description>
  </link>
  <reference>
    <citation>Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther. 2006;11(6):797-802.</citation>
    <PMID>17310824</PMID>
  </reference>
  <reference>
    <citation>Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359-62.</citation>
    <PMID>2523562</PMID>
  </reference>
  <reference>
    <citation>Cornberg M, Deterding K, Manns MP. Present and future therapy for hepatitis C virus. Expert Rev Anti Infect Ther. 2006 Oct;4(5):781-93. Review.</citation>
    <PMID>17140355</PMID>
  </reference>
  <reference>
    <citation>Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep. 2002 Feb;4(1):23-30. Review.</citation>
    <PMID>11825538</PMID>
  </reference>
  <reference>
    <citation>Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004 Dec;40(6):1260-5.</citation>
    <PMID>15558712</PMID>
  </reference>
  <reference>
    <citation>Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H; North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008 Jan;47(1):35-42.</citation>
    <PMID>17975791</PMID>
  </reference>
  <reference>
    <citation>Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003 Apr;9(4):331-8.</citation>
    <PMID>12682882</PMID>
  </reference>
  <reference>
    <citation>Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S. Review.</citation>
    <PMID>9305658</PMID>
  </reference>
  <reference>
    <citation>Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S21-9. Review.</citation>
    <PMID>12407573</PMID>
  </reference>
  <reference>
    <citation>Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 Dec 18;315(25):1575-8.</citation>
    <PMID>3097544</PMID>
  </reference>
  <reference>
    <citation>Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52. Review.</citation>
    <PMID>11439948</PMID>
  </reference>
  <reference>
    <citation>Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609-17.</citation>
    <PMID>15972867</PMID>
  </reference>
  <reference>
    <citation>Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol. 1999;31 Suppl 1:39-42. Review.</citation>
    <PMID>10622558</PMID>
  </reference>
  <reference>
    <citation>Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.</citation>
    <PMID>11583749</PMID>
  </reference>
  <reference>
    <citation>Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006 Sep;55(9):1350-9. Review.</citation>
    <PMID>16905701</PMID>
  </reference>
  <reference>
    <citation>Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005 Sep;5(9):558-67. Review.</citation>
    <PMID>16122679</PMID>
  </reference>
  <reference>
    <citation>Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007 Jul 12;357(2):124-34.</citation>
    <PMID>17625124</PMID>
  </reference>
  <reference>
    <citation>von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005 Aug;129(2):522-7.</citation>
    <PMID>16083709</PMID>
  </reference>
  <reference>
    <citation>Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004 Jun;40(6):993-9. Erratum in: J Hepatol. 2005 Mar;42(3):434.</citation>
    <PMID>15158341</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 18, 2015</lastchanged_date>
  <firstreceived_date>December 4, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic HCV-genotype 2/3</keyword>
  <keyword>Efficacy of treatment extension</keyword>
  <keyword>PegIntron</keyword>
  <keyword>pegylated interferon alpha-2b</keyword>
  <keyword>Rebetol</keyword>
  <keyword>ribavirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
